Toronto, Ontario–(Newsfile Corp. – July 29, 2024) – Optimind Pharma Corp. (CSE: OMND) (“Optimind” or the “Company”) announces it has closed the second trance of its previously announced private placement. The Company issued 2,500,000 common shares at a price of $0.05 per share to investors for gross proceeds of $125,000.
The Company expects to close a third tranche of the private placement in the next couple of weeks.
Net proceeds will be used for working capital. All securities issued in connection with the private placement are subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.
Optimind Pharma is an emerging provider of psychedelic therapies. From specializing in prescribing medical cannabis, ketamine-assisted treatment, and other psychedelic-enhanced psychotherapy modalities, Optimind Pharma helps individuals suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities.
Optimind exists to combine the power of psychedelic medicine with the science of psychology to provide legal psychedelic enhanced psychotherapy in a safe, controlled environment.